Beam Therapeutics Inc. (NASDAQ:BEAM) Wells Fargo twentieth Annual Healthcare Convention 2025 September 4, 2025 1:30 PM EDT
Firm Individuals
John Evans – CEO & Director
Giuseppe Ciaramella – President
Convention Name Individuals
Yanan Zhu – Wells Fargo Securities, LLC, Analysis Division
Presentation
Yanan Zhu
Senior Fairness Analyst
Thanks, everybody, for being right here. My identify is Yanan Zhu. I am one of many biotech analysts right here at Wells Fargo. It’s my nice pleasure to introduce our subsequent fireplace chat. We’re privileged to have the Beam Therapeutics staff with us. And right here on stage are John Evans, CEO; and Pino Ciaramella, President of the corporate. Thanks, Pino, and thanks, John, for being right here.
John Evans
CEO & Director
Thanks for having us.
Query-and-Reply Session
Yanan Zhu
Wells Fargo Securities, LLC, Analysis Division
Nice. So I used to be questioning when you might begin off by offering an outline of the corporate and any upcoming catalysts that buyers ought to have in mind?
John Evans
CEO & Director
Positive. So Beam Therapeutics is a next-generation gene enhancing firm. We use an essential type of CRISPR known as base enhancing, wherein we use the identical precision focusing on means of CRISPR to edit any spot within the genome, however we have modified the system in order that it would not make double-stranded breaks the place you lose management of the sequence. As a substitute, we’re making exact single base adjustments on the goal website.
A lot extra exact and rather more predictability when it comes to the therapeutic final result that you will have, all for a sturdy onetime remedy for very severe ailments. We’re making use of this very broadly, however in all probability our core franchises are in 2 areas. One is hematology. So that is the place we take the blood cells, we edit them on to attempt to treatment illness, lead applications in sickle cell illness.
